April 3rd 2025
The move towards “pharma 4.0” requires a major shift, both ideologically and technologically, to adapt current processes to a framework that will automate much of today’s manufacturing.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Merck Signs Licensing Deal to Use Codexis’ Protein Engineering Technology
August 4th 2015The agreement gives Merck a non-exclusive license to use Codexis’ proprietary CodeEvolver protein engineering platform technology to develop novel enzymes for use in the manufacture of Merck’s pharmaceutical products.
Handling HPAPIs: Do Your CMOs Have the Right Stuff?
August 1st 2015Ignoring a contract partner’s ability to handle highly potent APIs (HPAPIs) safely may have serious consequences. Drug owners and contract service providers alike must understand the complexities and liabilities involved in working with HPAPIs.